Live-attenuated dengue vaccine development
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Eight of 69 (12%) healthy adult volunteers vaccinated with monovalent live-attenuated dengue virus (DENV) vaccine candidates had atypical antibody responses, with depressed IgM:IgG antibody ratios and induction of high-titer hemagglutination-inhibiting and neutralizing (NT) antibodies to all four DENV serotypes. These features suggested flavivirus exposure prior to DENV vaccination, yet no volunteer had a history of previous flavivirus infection, flavivirus vaccination, or antibody to flaviviruses evident before DENV vaccination. Moreover, production of antibody to DENV by atypical responders (AR) was not accelerated compared with antibody responses in the 61 flavivirus-naive responders (NR). Further evaluation revealed no differences in sex, age, race, DENV vaccine candidate received, or clinical signs and symptoms following vaccination between AR and NR. However, viremia was delayed at the onset in AR compared with NR. A comparative panel of all AR and five randomly selected NR found flavivirus cross-reactive antibody after vaccination only in AR. Unexpectedly, six of eight AR had NT antibodies to yellow fever virus (YFV) > 1:10 before vaccination while NR had none ( = 0.04). The AR also universally demonstrated YFV NT antibody titers ≥ 1:160 after DENV vaccination, whereas four of five NR failed to seroconvert ( = 0.02). Yellow fever virus priming broadens the antibody response to monovalent DENV vaccination. The effect of flavivirus priming on the clinical and immunologic response to tetravalent DENV vaccine remains to be determined.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE, 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70 : 37–43. [Google Scholar]
  2. Sabin AB, 1952. Research on dengue during World War II. Am J Trop Med Hyg 1 : 30–50. [Google Scholar]
  3. Makino Y, Tadano M, Saito M, Maneekarn N, Sittisombut N, Sirisanthana V, Poneprasert B, Fukunaga T, 1994. Studies on serological cross-reaction in sequential flavivirus infections. Microbiol Immunol 38 : 951–955. [Google Scholar]
  4. Price WH, Casals J, Thind I, O’Leary W, 1973. Sequential immunization procedure against Group B arboviruses using living attenuated 17D yellow fever virus, living attenuated Langat E5 virus, and living attenuated dengue 2 virus (New Guinea C isolate). Am J Trop Med Hyg 22 : 509–523. [Google Scholar]
  5. Libraty DH, Nisalak A, Endy TP, Suntayakorn S, Vaughn DW, Innis BL, 2002. Clinical and immunological risk factors for severe disease in Japanese encephalitis. Trans R Soc Trop Med Hyg 96 : 173–178. [Google Scholar]
  6. Schlesinger RW, Gordon I, Frankel JW, Winter JW, Patterson PR, Dorrance WR, 1956. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol 77 : 352–364. [Google Scholar]
  7. Carey D, Myers R, Rodrigues F, 1965. Two episodes of dengue fever, caused by type 4 and 1 viruses, in an individual previously immunized against yellow fever. Am J Trop Med Hyg 14 : 448–450. [Google Scholar]
  8. Scott RM, Eckels KH, Bancroft WH, Summers PL, McCown JM, Anderson JH, Russell PK, 1983. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis 148 : 1055–1060. [Google Scholar]
  9. Bancroft WH, Scott RM, Eckels KH, Hoke CH Jr, Simms TE, Jesrani KD, Summers PL, Dubois DR, Tsoulos D, Russell PK, 1984. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 149 : 1005–1010. [Google Scholar]
  10. Pond WL, Ehrenkranz NJ, Danauskas JX, Carter MJ, 1967. Heterotypic serologic responses after yellow fever vaccination; detection of persons with past St. Louis encephalitis or dengue. J Immunol 98 : 673–682. [Google Scholar]
  11. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo J-F, Hoke CH Jr, 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur, AvP) in human volunteers. Vaccine 19 : 3179–3188. [Google Scholar]
  12. Sun W, Edelman R, Kanesa-thasan N, Eckels KH, Putnak R, King AD, Houng H-S, Tang D, Scherer JM, Hoke CH Jr, Innis BL, 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69 (suppl): (in press). [Google Scholar]
  13. Yuill TM, Sukhavachana P, Nisalak A, Russell PK, 1968. Dengue-virus recovery by direct and delayed plaques in LLC-MK2 cells. Am J Trop Med Hyg 17 : 441–448. [Google Scholar]
  14. Eckels KH, Brandt WE, Harrison VR, McCown JM, Russell PK, 1976. Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infect Immun 14 : 1221–1227. [Google Scholar]
  15. Clarke DH, Casals J, 1958. Techniques for hemagglutination and hemagglutination inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7 : 561–573. [Google Scholar]
  16. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH Jr, 1989. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 40 : 418–427. [Google Scholar]
  17. Trofa AF, DeFraites RF, Smoak BL, Kanesa-thasan N, King AD, Burrous JM, MacArthy PO, Rossi C, Hoke CH Jr, 1997. Dengue fever in US military personnel in Haiti. JAMA 277 : 1546–1548. [Google Scholar]
  18. Russell PK, Nisalak A, Sukhavachana P, Vivona S, 1967. A plaque reduction test for dengue virus neutralization antibodies. J Immunol 99 : 285–290. [Google Scholar]
  19. Nimmannitya S, Halstead SB, Cohen S, Margiotta MR, 1969. Dengue and chikungunya virus infection in man in Thailand, 1962–1964. I. Observations on hospitalized patients with hemorrhagic fever. Am J Trop Med Hyg. 18 : 954–971. [Google Scholar]
  20. Russell PK, Intavivat A, Kanchanapilant S, 1969. Anti-dengue immunoglobulins and serum beta 1 c/a globulin levels in dengue shock syndrome. J Immunol 102 : 412–420. [Google Scholar]
  21. Calisher CH, 1994. Medically important arboviruses of the United States and Canada. Clin Microbiol Rev 7 : 89–116. [Google Scholar]
  22. Niedrig M, Lademann M, Emmerich P, Lafrenz M, 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4 : 867–871. [Google Scholar]
  23. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, 1981. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59 : 895–900. [Google Scholar]
  24. Theiler M, Casals J, 1958. The serological reactions in yellow fever. Am J Trop Med Hyg 7 : 585–594. [Google Scholar]
  25. Wisseman CL Jr, Sweet BH, 1962. Immunological studies with group B arthropod-borne viruses: I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus. Am J Trop Med Hyg 11 : 550–561. [Google Scholar]
  26. Sweet BH, Wisseman CL Jr, Kitaoka M, Tamiya T, 1962. Immunological studies with group B arthropod-borne viruses: II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subjects following administration of 17D yellow fever vaccine. Am J Trop Med Hyg 11 : 562–569. [Google Scholar]
  27. Kayser M, Klein H, Paasch I, Pilaski J, Blenk H, Heeg K, 1985. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. J Med Virol 17 : 35–45. [Google Scholar]
  28. Kurane I, Okamoto Y, Dai LC, Zeng LL, Brinton MA, Ennis FA, 1995. Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8- cytotoxic T lymphocyte clones. J Gen Virol 76 : 2243–2249. [Google Scholar]
  29. Bot A, Bot S, Bona CA, 1998. Protective role of gamma interferon during the recall response to influenza virus. J Virol 72 : 6637–6645. [Google Scholar]
  30. Guzman JR, Kron MA, 1997. Threat of dengue haemorrhagic fever after yellow fever vaccination (letter). Lancet 349 : 1841. [Google Scholar]
  31. Eckels KH, Kliks SC, Dubois DR, Wahl LM, Bancroft WH, 1985. The association of enhancing antibodies with seroconversion in humans receiving a dengue-2 live-virus vaccine. J Immunol 135 : 4201–4203. [Google Scholar]
  32. Bancroft WH, Top FH Jr, Eckels KH, Anderson JH Jr, McCown JM, Russell PK, 1981. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun 31 : 698–703. [Google Scholar]
  33. Price WH, 1968. Sequential immunization as a vaccination procedure against dengue viruses. Am J Epidemiol 88 : 392–397. [Google Scholar]
  34. Halstead SB, Casals J, Shotwell H, Palumbo N, 1973. Studies on the immunization of monkeys against dengue I. protection derived from single and sequential virus infections. Am J Trop Med Hyg 22 : 365–374. [Google Scholar]
  35. Halstead SB, Palumbo NE, 1973. Studies on the immunization of monkeys against dengue: II. Protection following inoculation of combinations of viruses. Am J Trop Med Hyg 22 : 375–381. [Google Scholar]
  36. Wisseman CL Jr, Kitaoka M, Tamiya T, 1966. Immunological studies with group B arthropod-borne viruses V. Evaluation of cross-immunity against type 1 dengue fever in human subjects convalescent from subclinical natural Japanese encephalitis virus infection and vaccinated with 17D strain yellow fever vaccine. Am J Trop Med Hyg 15 : 588–600. [Google Scholar]

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error